<b id="19ndx"><address id="19ndx"></address></b>

    <b id="19ndx"></b>
    
    

    <mark id="19ndx"><thead id="19ndx"></thead></mark>

    <meter id="19ndx"></meter>
    <delect id="19ndx"><sub id="19ndx"><noframes id="19ndx">

    鏀惰棌-鍋ュ悍緗戜細鍛樿闂褰?/h3>

    緗戦〉鏍囬錛?

    娉ㄥ唽鍋ュ悍緗戠敤鎴?/h3>

    鐢?鎴?鍚嶏細
    鑱?緋?浜猴細
    鎬?nbsp; 鍒細
    瀵?nbsp; 鐮侊細
    閲嶅瀵嗙爜錛?/th>
    鐢靛瓙閭錛?/th>
    閭楠岃瘉鐮侊細
    鍥哄畾鐢佃瘽錛?/th>
    浼?nbsp; 鐪燂細
    鎵?nbsp; 鏈猴細
    鍗曚綅鍚嶇О錛?/th>
    閫氫俊鍦板潃錛?/th>
    棣栭€夋爮鐩細
    鎴戝凡緇忚鐪熼槄璇誨茍鍚屾剰銆婂仴搴風綉鏈嶅姟鏉℃銆?/a>

    鎵懼洖瀵嗙爜

    • 1.閫夋嫨鎵懼洖鏂瑰紡
    • 2.紜楠岃瘉淇℃伅
    • 3.淇敼瀵嗙爜
    • 4.淇敼鎴愬姛
    • 鎵懼洖鏂瑰紡錛?/span>
    • 鐢?鎴?鍚嶏細
    • 鎵嬫満鍙風爜錛?/span>

    鑻卞浗鑽洃鏈烘瀯錛圡HRA錛夊叧浜?0mg/ml鐩愰吀鑳虹閰敞灝勬恫娼滃湪緇撴櫠闂娌熼€氬嚱錛堝師鏂囷級

    浣滆€咃細浣氬悕   鏉ユ簮錛氳嫳鍥借嵂鐩戞満鏋?nbsp;   鐐瑰嚮鏁幫細0    鏇存柊鏃墮棿錛?024-3-1 16:05:31

    [鍏抽敭瀛梋錛?/font>
    鑽墿璀︽垝 鐩愰吀鑳虹閰敞灝勬恫

    鍋ュ悍緗戣錛?/FONT>

    Direct Healthcare Professional Communication

     

    24th August 2021

     

    Amiodarone Hydrochloride 50 mg/ml Concentrate for Solution for Injection/Infusion - Potential for crystallisation

     

     

    Dear Healthcare professional,

     

    In agreement with the Medicines and Healthcare products Regulatory Agency (MHRA), the UK Marketing Authorisation Holders of products containing amiodarone hydrochloride 50 mg/ml concentrate, namely hameln pharma gmbh, Bowmed Ibisqus Limited/ Ibigen S.r.l. Aventis Pharma Limited trading as Sanofi, would like to inform you of the following:

     

    Reports have been received of visible crystals of amiodarone hydrochloride within the solution of a small number of ampoules of marketed product

     

    Healthcare professionals are advised to:

     

    Visually inspect ampoules of amiodarone for clarity, particulate matter, discolouration the integrity of the container

          Only use the solution if it is clear the container is undamaged intact

     

     

    Background information

     

    Amiodarone hydrochloride is an antiarrhythmic used for the management of life-threatening ventricular arrhythmias (tachycardia or fibrillation) and supraventricular arrhythmias (fibrillation or flutter) and Wolff-Parkinson-White Syndrome.

     

    The potential for amiodarone solutions to crystallise and the associated potential for amiodarone- induced phlebitis are known have been previously discussed in the scientific literature [1, 2].

     

    Amiodarone in aqueous solution is associated with crystallisation due to poor solubility. To overcome this, the molecule is typically solubilised as part of a micellar system using an excipient, such as polysorbate 80, which acts as a surfactant. Any breakdown of this micellar system can lead to crystallisation of amiodarone in solution, which has been observed both at high concentrations of amiodarone (e.g. in ampoules of concentrate) and at low concentrations (e.g. in infusion bags during administration).

     

    While the potential for amiodarone solutions to crystallise is known, following receipt of a small number of reports of crystallisation in ampoules from separate batches of product, and the subsequent investigations undertaken, the Marketing Authorisation Holders would like to highlight this potential for crystallisation to healthcare professionals.

     

    Adverse reactions

     

    As noted in the prescribing information for the products, infusion phlebitis is listed as one of the most common adverse drug effects reported with intravenous amiodarone hydrochloride.

     

    There has been no identified increase in the reporting of adverse reactions that would be considered related to the crystallisation of amiodarone during infusion (e.g. phlebitis, thrombophlebitis). While this doesn鈥檛 exclude the possibility of adverse health consequences, it further supports the overall probability that the occurrence of such reactions is low.

     

    Recommendations for use

     

    To inform healthcare professionals of the potential for crystallisation, the Marketing Authorisation Holders, in agreement with the MHRA, have issued this Direct Healthcare Professional Communication to provide additional information for healthcare professionals.

     

    Healthcare professionals should continue to follow the advice below:

     

    Before use, the sterile concentrate should be visually inspected for clarity, particulate matter, discolouration the integrity of the container. The solution should only be used if it is clear the container is undamaged intact.

     

    Although the use of in-line filters is not considered to be standard practice in the UK for all infusions of medicinal products, healthcare professionals may wish to consider the use of in-line filters for infusions of solutions that are known to crystallise, including solutions of amiodarone [1,2].

     

    Call for reporting

     

    Please continue to report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow

    Card Scheme. Please report:

         all suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal,

    life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason;

        all suspected ADRs associated with new drugs and vaccines identified by the black triangle鈻?

     

    It is easiest quickest to report ADRs online via the Yellow Card website - https://yellowcard.mhra.gov.uk/ or via the Yellow Card app available from the Apple App Store or Google Play Store.

     

    Report via

     

        the Yellow Card website https://yellowcard.mhra.gov.uk/

         the free Yellow Card app available from the Apple App Store or Google Play Store

        some clinical IT systems (EMIS, SystmOne, Vision, MiDatabank) for healthcare professionals. Suspected side effect can also be reported by calling 0800 731 6789 for free.

    When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, treatment dates, product brname.


    Company contacts

     

    This letter concerns all amiodarone hydrochloride 50 mg/ml concentrate medicinal products that are licensed in the UK has been agreed by the below listed companies.

     

     

    Marketing Authorisation

    Holder

    Registered Product Name

    Contact details

    hameln pharma gmbh

    Amiodarone Hydrochloride 50 mg/ml Concentrate for

    Solution for Injection/Infusion

    hameln pharma ltd

    Nexus, Gloucester Business Park

    Gloucester, GL3 4AG Tel: 01452 621 661

     

    drug.safety@hameln- pharma.co.uk

    Bowmed Ibisqus Limited/ Ibigen S.r.l.

    Amiodarone 150 mg/3 ml

    Concentrate   for Solution for

    Injection/Infusion

    Bowmed Ibisqus Limited

    The Old Dairy,

    Brynkinalt Business Centre

    Brynkinalt, Chirk,   Tel: 01483 212 151

     

    medinfo@bowmed.com

    Aventis Pharma Limited

    Trading   as Sanofi

    Cordarone X 150 mg/3 ml

    Solution   for Injection

    Sanofi

    410 Thames Valley Park Drive   Reading, Berkshire, RG6 1PT Tel: 0800 035 2525

     

    uk-medicalinformation@sanofi.com

     

     

    Signed on behalf of the above MA Holders

     

    RCK1}~(}QR~(BOLRG)R9P)F.png

     

    Richard Wysocki MRPharmS

    Medical Affairs Director, hameln pharma ltd

     

     

    References

     

    1)     Phlebitis in Intravenous Amiodarone Administration: Incidence and Contributing Factors. Crit Care Nurse (2019) 39 (1): e1鈥?/span>

    e12 https://aacnjournals.org/ccnonline/article/39/1/e1/20866/Phlebitis-in-Intravenous-Amiodarone-Administration

     

    2)     Phlebitis in Amiodarone Administration. Incidence, Contributing Factors, Clinical Implications. Am J Crit Care (2013) 22 (6): 498-505 https://medest118.files.wordpress.com/2013/12/phlebitis-in-amiodarone-administration.pdf


    成人毛片在线,久久这里只有精品免费视频,日韩看片网站,日本亚洲乱码中文字幕影院
    <b id="19ndx"><address id="19ndx"></address></b>

      <b id="19ndx"></b>
      
      

      <mark id="19ndx"><thead id="19ndx"></thead></mark>

      <meter id="19ndx"></meter>
      <delect id="19ndx"><sub id="19ndx"><noframes id="19ndx">